Patents Examined by Svetlana M Ivanova
  • Therapeutic targeting of interleukin-1 receptor-associated kinase 4 (IRAK4) in cancers characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
    Patent number: 10640502
    Abstract: Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: May 5, 2020
    Assignee: Northwestern University
    Inventors: Ali Shilatifard, Kaiwei Liang, Edwin Richard Smith, Gary E. Schiltz
  • Spironolactone aqueous compositions
    Patent number: 10624906
    Abstract: Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: April 21, 2020
    Assignee: CMP Development LLC
    Inventors: Anthony Pipho, Michael Paul DeHart
  • Hepatitis C virus inhibitors
    Patent number: 10617675
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: April 14, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: David B. Frennesson, Piyasena Hewawasam, Omar D. Lopez, Van N. Nguyen, Mark G. Saulnier, Yong Tu, Alan Xiangdong Wang, Gan Wang, Ningning Xu, Roshan Yadavrao Nimje, Hasibur Rahaman, Samayamunthula Venkata Satya Arun Kumar Gupta, Nicholas A. Meanwell, Makonen Belema
  • Use of hydroxycarbamide for preventing retinal nonperfusion
    Patent number: 10617658
    Abstract: The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: April 14, 2020
    Assignees: CENTRE HOSPITALIER NATIONAL D'OPHTALMOLOGIE QUINZE-VINGTS, INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICAL (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PARIS DESCARTES
    Inventors: Yves Colin, Jean-Francois Girmens, Olivier Hermine, Emmanuel Heron, Michel Paques
  • Liquid formulations of fosaprepitant
    Patent number: 10610532
    Abstract: The present invention relates to liquid formulations of Fosaprepitant intended for parenteral administration. Further the invention also describes process for preparing such formulations.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: April 7, 2020
    Assignee: LEIUTIS PHARMACEUTICALS PVT. LTD.
    Inventors: Kocherlakota Chandrashekhar, Banda Nagaraju
  • Compositions and methods relating to RAD6 inhibition
    Patent number: 10588985
    Abstract: Pharmaceutical compositions, methods of treatment of proliferative diseases and commercial packages are provided according to aspects of the present invention which relate to a first therapeutic agent coupled to a nanoparticle, wherein the first therapeutic agent is SMI #8 or SMI #9 a pharmaceutically acceptable salt, ester, amide, stereoisomer, hydrate, or derivative of either thereof. According to particular aspects, the SMI #8 or SMI #9 is conjugated to gold nanoparticles.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: March 17, 2020
    Assignee: Wayne State University
    Inventors: Malathy Shekhar, Guangzhao Mao, Yanhua Zhang
  • CNS-accessible pharmacological chaperones for treatment of acid ?-glucosidase-related disease states
    Patent number: 10588888
    Abstract: Disclosed herein are ?-glucosidase (GCase) chaperones and methods of using GCase chaperones in an individual in need thereof. GBA1 mutations lead to GCase deficiency and substrate accumulation, causing Gaucher disease. Currently, no FDA or EMA-approved therapeutic for neuronopathic Gaucher disease is available. Improved GCase activity in brain cells using a chaperone may reduce substrate accumulation and associated pathology. Disclosed herein are novel non-inhibitory chaperone compounds of GCase that have properties of a central nervous system drug. Those compounds effectively restored mutant GCase activity by stabilizing protein and enhancing lysosomal localization and may be useful for chaperone therapy to treat neuronopathic Gaucher disease and likely to Parkinson's disease.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: March 17, 2020
    Assignee: Children's Hospital Medical Center
    Inventors: Ying Sun, Zhaolin Wang
  • Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
    Patent number: 10576067
    Abstract: Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: March 3, 2020
    Assignee: Ankh Life Sciences Limited
    Inventors: Gene H. Zaid, Thomas W. Burgoyne
  • Method of controlling phytopathogenic diseases on turfgrass
    Patent number: 10568327
    Abstract: The present invention relates to a method of controlling dollar spot on turfgrass, in particular low to moderate disease pressure, using a fungicidally effective non-phytotoxic amount of (A) chlorothalonil and (B) acibenzolar-s-methyl.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: February 25, 2020
    Assignee: Syngenta Participations AG
    Inventors: John Robert James, Michael Agnew
  • Methods of treatment using a JAK inhibitor compound
    Patent number: 10548886
    Abstract: The invention relates to methods of treating ocular diseases and certain respiratory diseases using the compound 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol or a pharmaceutically-acceptable salt thereof.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: February 4, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Melanie A. Kleinschek, Glenn D. Crater
  • Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
    Patent number: 10532043
    Abstract: Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: January 14, 2020
    Assignee: Ankh Life Sciences Limited
    Inventors: Gene H. Zaid, Thomas W. Burgoyne
  • Method of controlling phytopathogenic diseases on turfgrass
    Patent number: 10524474
    Abstract: The present invention relates to a method of controlling pythium blight on turfgrass, in particular low to moderate disease pressure, using a fungicidally effective non-phytotoxic amount of (A) chlorothalonil and (B) acibenzolar-s-methyl.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: January 7, 2020
    Assignee: Syngenta Participations AG
    Inventors: John Robert James, Michael Agnew
  • Methods and compositions for treating diabetes, metabolic syndrome and other conditions
    Patent number: 10517868
    Abstract: Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: December 31, 2019
    Assignee: Strongbridge Dublin Limited
    Inventor: Per Marin
  • Method of controlling phytopathogenic diseases on turfgrass
    Patent number: 10517298
    Abstract: The present invention relates to a method of controlling bacterial wilt on turfgrass, in particular low to moderate disease pressure, using an effective non-phytotoxic amount of (A) chlorothalonil and (B) acibenzolar-s-methyl.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: December 31, 2019
    Assignee: Syngenta Participations AG
    Inventor: Michael Agnew
  • Therapeutic agents for treating diseases associated with chronic inflammation and screening method
    Patent number: 10512639
    Abstract: A method for treating autoimmune diseases or a disease associated with chronic inflammation can include administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an Arid5a inhibitor and a pharmaceutically acceptable carrier. The Arid5a inhibitor can have the formula or a pharmaceutically acceptable salt thereof. The disease associate with chronic inflammation can be multiple sclerosis. A screening method can include identifying candidate Arid5a inhibitors through in silico predicted binding to Arid5a target domains and confirming Arid5a inhibition through in vitro binding assays.
    Type: Grant
    Filed: April 28, 2019
    Date of Patent: December 24, 2019
    Assignee: King Faisal University
    Inventor: Hamza Naim Ahmad Hanieh
  • Therapeutics compositions containing harmine and isovanillin components, and methods of use thereof
    Patent number: 10507200
    Abstract: Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: December 17, 2019
    Assignee: Ankh Life Sciences Limited
    Inventors: Gene H. Zaid, Thomas W. Burgoyne
  • Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage
    Patent number: 10500181
    Abstract: Methods and compositions for treating a complication associated with aneurysmal subarachnoid hemorrhage (SAH), the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof. Methods and compositions for treating vasospasm, the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: December 10, 2019
    Assignee: Vanderbilt University
    Inventors: Marshall L. Summar, Frederick E. Barr, Reid Carleton Thompson
  • Spironolactone aqueous compositions
    Patent number: 10493083
    Abstract: Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: December 3, 2019
    Assignee: CMP Development LLC
    Inventors: Anthony Pipho, Michael Paul DeHart
  • Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
    Patent number: 10493080
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: December 3, 2019
    Assignees: The Scripps Research Institute, Novartis AG
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
  • Methods of treating behavioral syndromes using pipradrol
    Patent number: 10493069
    Abstract: Methods of treating behavioral syndromes by administering a pharmaceutical composition of pipradrol or a pharmaceutically acceptable salt thereof are provided. The methods may be used to treat Attention-Deficit Disorder (ADD) and Attention-Deficit Hyperactivity Disorder (ADHD).
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: December 3, 2019
    Assignee: OVID THERAPEUTICS INC.
    Inventor: Matthew During